Weight Loss News 10 September 2025

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its

17 October 2025

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Stock Performance (Sep 2025) On Sept 30, 2025 Pfizer closed around $24.40 reuters.com. Over the past year PFE underperformed the pharma sector (latest 52-week range ~$20.91–30.43 reuters.com). Its trailing P/E is 12.64× reuters.com (ex. special items) and forward P/E ~7.7×

30 September 2025

Business News · NYSE:PFE · Pharmaceuticals · Stock Market · Stocks · Trump Administration · Weight Loss

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

“It’s never been more clear that we are delivering exactly what millions of people have been waiting for,” said HIMS CEO Andrew Dudum after Q2 results investors.hims.com. With analysts ranging from “Sell” to “Buy”, and social media buzzing, Hims &

29 September 2025

FDA Regulation · Healthcare Stocks · Investment News · Market Trends · NYSE:HIMS · Stock Market · Weight Loss

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Trial Results: Big Early Losses, Then Weight Loss Levels Off This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants

17 September 2025

Clinical Trials · Eli Lilly · NYSE:LLY · NYSE:NVO · Obesity Drugs · Pharma News · Weight Loss

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases

GLP-1 Receptor Agonists and Neurodegenerative Diseases in 2025 GLP-1 receptor agonists like semaglutide (Ozempic®) are typically given via a weekly injection pen. Originally developed for diabetes and obesity, these drugs are now being studied for their effects on the brain.

10 September 2025

Alzheimer’s · GLP-1 Drugs · Medicine · Neurodegenerative Diseases · NYSE:NVO · Weight Loss

Weight Loss News 10 September 2025 - 17 October 2025

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Ozempic for Alzheimer’s? How GLP-1 Weight-Loss Drugs Could Fight Neurodegenerative Diseases